Substrate Fragmentation for the Design of M. tuberculosis CYP121 Inhibitors

Madeline E. Kavanagh, Janine L. Gray, Sophie H. Gilbert, Anthony G. Coyne, Kirsty Mclean, Holly J. Davis, Andrew Munro, Chris Abell

    Research output: Contribution to journalArticlepeer-review

    94 Downloads (Pure)


    The cyclo-dipeptide substrates of the essential M. tuberculosis (Mtb) enzyme CYP121 were deconstructed into their component fragments and screened against the enzyme. A number of hits were identified, one of which exhibited an unexpected inhibitor-like binding mode. The inhibitory pharmacophore was elucidated, and fragment binding affinity was rapidly improved by synthetic elaboration guided by the structures of CYP121 substrates. The resulting inhibitors have low micromolar affinity, good predicted physicochemical properties and selectivity for CYP121 over other Mtb P450s. Spectroscopic characterisation of the inhibitors′ binding mode provides insight into the effect of weak nitrogen-donor ligands on the P450 heme, an improved understanding of factors governing CYP121–ligand recognition and speculation into the biological role of the enzyme for Mtb.
    Original languageEnglish
    Pages (from-to)1924-1935
    Number of pages12
    Issue number17
    Early online date19 Jul 2016
    Publication statusPublished - 2016


    • drug discovery
    • enzymes
    • · fragment-based methods
    • substrate analogues
    • tuberculosis

    Research Beacons, Institutes and Platforms

    • Biotechnology
    • Manchester Institute of Biotechnology


    Dive into the research topics of 'Substrate Fragmentation for the Design of M. tuberculosis CYP121 Inhibitors'. Together they form a unique fingerprint.

    Cite this